STOCK TITAN
  1. Home
  2. News
  3. OPK

Opko Health - OPK STOCK NEWS

Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.

OPKO Health Inc. (NASDAQ: OPK) is a diversified healthcare company focused on establishing leading positions in large, rapidly growing markets. OPKO operates through two main segments: Diagnostics and Pharmaceuticals.

OPKO's Diagnostics segment includes BioReference Laboratories, the nation's third largest clinical laboratory. BioReference offers a comprehensive range of diagnostic services and features a core genetic testing business supported by a skilled 400-person sales and marketing team. Notable products include the 4Kscore® test for prostate cancer and the Claros® 1 in-office immunoassay platform.

The Pharmaceutical segment of OPKO showcases a diverse portfolio of products. Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency, was launched in November 2016. Other significant pharmaceutical developments include Varubitm for chemotherapy-induced nausea and vomiting, OPK88004 for type 2 diabetes and obesity, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia, both of which are in Phase 2 clinical trials.

OPKO has recently made headlines with strategic collaborations and technological advancements. BioReference Health, a subsidiary of OPKO, has entered a strategic alliance with SOPHiA GENETICS to incorporate MSK-ACCESS® liquid biopsy technology. This partnership aims to enhance BioReference's genomic analysis capabilities and offer state-of-the-art cancer testing across the U.S. Another collaboration with Prognos Health aims to merge genomic data with real-world data, facilitating precision medicine and improving patient outcomes.

Financially, OPKO continues to exhibit a strong performance with ongoing projects and strategic acquisitions. The acquisition of select assets from BioReference Health by Labcorp is set to expand OPKO's reach and capabilities, strengthening its market presence.

Headquartered in Miami, Florida, OPKO Health is committed to improving healthcare through innovation, scientific expertise, and strategic partnerships. For more detailed information about their products, services, and latest news, visit www.opko.com.

News

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) reported business highlights and financial results for the fourth quarter and full year 2023. Key highlights include advancements in ModeX's pipeline, global approvals for NGENLA, and BioReference Health's REACH program. Financially, revenue from products increased, while operating losses widened. The company also completed a significant convertible notes offering post-quarter-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
earnings
-
News

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Rhea-AI Summary
OPKO Health, Inc. (OPK) is set to announce its operating and financial results for the three and 12 months ending December 31, 2023. The company's senior management will provide a business update and discuss financial guidance during a conference call on February 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences earnings
-
News

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the closing of a private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029, as well as a concurrent private placement of approximately $71.1 million aggregate principal amount of Convertible Senior Notes due 2029 to Frost Gamma Investments Trust, affiliated with the Company's Chairman and Chief Executive Officer. The Company received estimated net proceeds of approximately $221.4 million from the offering and used approximately $50.0 million of the net proceeds to repurchase shares of common stock from purchasers of Notes in privately negotiated transactions. Additionally, the Company repurchased for cash approximately $144.4 million aggregate principal amount of the Company’s outstanding 4.50% Convertible Senior Notes due 2025. The Notes and any shares of the common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act of 1933, as amended.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
offering
News

OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
OPKO Health, Inc. (OPK) to participate in the 42nd Annual J.P. Morgan Healthcare Conference, hosting one-on-one meetings with investors and presenting on January 10th. The presentation will be webcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.36%
Tags
conferences
-
News

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029. The Notes will bear interest at a rate of 3.75% per annum, payable semiannually, and will mature on January 15, 2029. The Company also entered into separate, privately negotiated transactions to repurchase approximately $144.4 million aggregate principal amount of its outstanding 4.50% Convertible Senior Notes due 2025. The net proceeds from the offering will be approximately $192.5 million, with approximately $50.0 million to be used for repurchasing shares of common stock from purchasers of Notes in privately negotiated transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
offering
-
News

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announces private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 with the option to purchase an additional $30.0 million. The Company expects to use the proceeds for repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.33%
Tags
offering
News

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Rhea-AI Summary
BioReference Health, LLC (BRH) has announced a strategic collaboration with Prognos Health to offer unique solutions for healthcare providers and researchers. The partnership aims to combine genetic data and critical biomarkers to provide targeted precision therapies based on patients' genetic profiles. This collaboration will utilize Prognos Health's managed real world data marketplace, which contains over 325 million de-identified patient health records, to accelerate the development and delivery of innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Rhea-AI Summary
SOPHiA GENETICS announced that BioReference Health, LLC will implement its technology and add MSK-ACCESS liquid biopsy to its test suite, making it the first laboratory globally to adopt this technology. The offering will be commercially available for ordering by healthcare providers through BioReference and its specialty division, GenPath Oncology, in 2024. The new liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Rhea-AI Summary
OPKO Health, Inc. reports business highlights and financial results for the third quarter of 2023. ModeX Therapeutics awarded a $59 million contract from BARDA for the development of multispecific antibodies against viral infectious diseases. NGENLA approved in 48 markets, sales underway in 23 countries. New clinical data on RAYALDEE® presented at Kidney Week 2023. OPKO Biologics enters research collaboration agreement with Entera Bio Ltd. for oral peptide tablet formulations. BioReference Health implementing initiatives to return to profitability. Consolidated total revenues for Q3 2023 were $178.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings

FAQ

What is the current stock price of Opko Health (OPK)?

The current stock price of Opko Health (OPK) is $1.68 as of February 21, 2025.

What is the market cap of Opko Health (OPK)?

The market cap of Opko Health (OPK) is approximately 1.1B.

What does OPKO Health Inc. specialize in?

OPKO Health Inc. specializes in diagnostics and pharmaceuticals, focusing on genetic testing and treatments for chronic diseases.

What are the main products offered by OPKO Health?

Key products include the 4Kscore® prostate cancer test, Rayaldee for secondary hyperparathyroidism, and Varubitm for chemotherapy-induced nausea.

What recent collaborations has OPKO Health announced?

OPKO Health's BioReference Health has partnered with SOPHiA GENETICS for genomic analysis and Prognos Health for real-world data integration.

Where is OPKO Health headquartered?

OPKO Health is headquartered in Miami, Florida.

What is the significance of the 4Kscore® test?

The 4Kscore® test is a blood test that helps assess the risk of aggressive prostate cancer, aiding in early detection and treatment planning.

How does BioReference Laboratories fit into OPKO Health's operations?

BioReference Laboratories is a key component of OPKO's diagnostics segment, offering comprehensive clinical and genetic testing services.

What is Rayaldee used for?

Rayaldee is used to treat secondary hyperparathyroidism in patients with stage 3-4 chronic kidney disease and vitamin D insufficiency.

What impact will the Labcorp acquisition have on OPKO Health?

The acquisition will expand OPKO's capabilities and market reach, enhancing its diagnostic services and overall market presence.

What are the future goals of OPKO Health?

OPKO aims to establish industry-leading positions in rapidly growing markets by leveraging its innovative technologies and strategic partnerships.

How can investors learn more about OPKO Health's performance?

Investors can visit OPKO's official website at www.opko.com for detailed information on financial performance, product updates, and strategic initiatives.
Stock OPK logo
Opko Health

Nasdaq:OPK

OPK Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

OPK Stock Data

1.12B
300.65M
54.51%
27.75%
13.07%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States
MIAMI